Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

Keeping up with solid Glycogen levels can be trying in the present speedy world. With SweetRelief Glycogen Support Canada, dealing with your Glycogen pressure, Glycogen sugar levels, and cholesterol ...

Keybioscience AG and Eli Lilly & Co. have agreed to extend their collaboration on the development of dual amylin and calcitonin receptor agonists (DACRAs), a new class of potential treatments for ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its GLP-1 and amylin receptor agonist candidates. Metsera is teaming up ...

The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...

In vitro and in vivo studies show that islet amyloid polypeptide (IAPP; also known as amylin)23 can potentiate Aβ aggregation by colocalising in brain parenchyma.24 The increased peripheral ...